ArticleJCI insight2016
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.
Abstract read
In one paragraph
Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Impact of Previous Local Treatment for Brain Metastases on Response to Molecular Targeted Therapy in BRAF-Mutant Melanoma Brain Metastasis: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers.Frontiers in oncology · 2021Pooled it
- Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review.Frontiers in immunology · 2021Pooled it
- Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Cancer letters · 2026Review
- Innate Immune Cells in Non-Small Cell Lung Cancer: Roles in Tumor Progression and Therapeutic Responses.Cancer innovation · 2026Review
- RAS signaling at the crossroads of radioresistance and tumor immunity.Journal for immunotherapy of cancer · 2026Review
- Spatially fractionated radiotherapy and immunotherapy: a synergistic strategy for systemic anti-tumor immunity.Journal of translational medicine · 2026Review
- The Double-Edged Sword: How Radiotherapy Shapes the Tumor Immune Microenvironment to Modulate Responses to Checkpoint Inhibitors.International journal of molecular sciences · 2026Review
- Beyond local control: radiotherapy-immunotherapy combinations fromFrontiers in genetics · 2026Review
- Immunotherapy combined with radiotherapy for advanced non-small cell lung cancer: Current status and challenge (Review).Oncology letters · 2025Review
- Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategies.Cell reports. Medicine · 2025Review
- [Advances in Radiotherapy for Extensive-stage Small Cell Lung Cancer in the Era of Immunotherapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization.Cancer immunology, immunotherapy : CII · 2025Article
- The Optimal Radiotherapy Strategy for Patients With Small Cell Lung Cancer and Brain Metastasis: A Retrospective Analysis.CNS neuroscience & therapeutics · 2024Article
- Article
- Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma.Journal of gastroenterology · 2024Article
- Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?Pharmaceuticals (Basel, Switzerland) · 2024Review
- Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment.Cancer immunology, immunotherapy : CII · 2024Article
- The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1.Japanese journal of radiology · 2024Review
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Grit S Herter-SprieDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Shohei KoyamaDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Houari KorideckDivision of Medical Physics and Biophysics, and.
Josephine HaiDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Jiehui DengDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Yvonne Y LiDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Kevin A BuczkowskiDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Aaron K GrantDivision of MRI Research, Department of Radiology, and.
Soumya UllasLongwood Small Animal Imaging Facility, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Kevin RheeDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Jillian D CavanaughDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Neermala Poudel NeupaneDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Camilla L ChristensenDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Jan M HerterCenter for Excellence in Vascular Biology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
G Mike MakrigiorgosDivision of Medical Physics and Biophysics, and.
F Stephen HodiDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Gordon J FreemanDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Glenn DranoffDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Peter S HammermanDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Alec C KimmelmanDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Kwok-Kin WongDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Funding
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3MTherapeutic strategies for specific subsets of KRAS mutant lung cancersR01CA140594 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WONG, KWOK KIN · 2009 to 2017
$4.5MTherapeutic approaches for LKB1-deficient non-small cell lung cancerR01CA205150 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., WONG, KWOK KIN · 2016 to 2020
$3.0MNetwork organization of the human autophagy systemR01GM095567 · NIGMS · HARVARD MEDICAL SCHOOL · PI HARPER, JEFFREY W, KIMMELMAN, ALEC · 2011 to 2018
$3.0MIn vivo analysis of EGFR mutant driven lung cancers responses to radiation therapR01CA122794 · NCI · DANA-FARBER CANCER INST · PI WONG, KWOK KIN · 2006 to 2015
$2.8MInvestigating the Role of Autophagy in Pancreatic Cancer Radiation ResistanceR01CA157490 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIMMELMAN, ALEC · 2011 to 2018
$2.5MIn vivo murine models of metastasis for therapeutic testingR01CA163896 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHARPLESS, NORMAN E, WONG, KWOK KIN · 2012 to 2016
$2.0MCredentialing Mouse Models for Immune System Therapy ResearchR01CA195740 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, WONG, KWOK KIN · 2015 to 2017
$1.8MMouse Models of Metastatic Triple-Negative Breast Cancer for Therapeutic TestingR01CA195754 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, ROSEN, JEFFREY MARK · 2015 to 2017
$1.7MInvestigating a Novel Glutamine Metabolism Pathway in Pancreatic CancerR01CA188048 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIMMELMAN, ALEC · 2015 to 2018
$1.5MNCI NIH HHS R01 CA122794NCI NIH HHS R01 CA140594NCI NIH HHS R01 CA157490NCI NIH HHS R01 CA163896NCI NIH HHS R01 CA166480NCI NIH HHS R01 CA188048NCI NIH HHS R01 CA195740NCI NIH HHS R01 CA195754NCI NIH HHS R01 CA205150NIGMS NIH HHS R01 GM095567
Abstract
Radiation therapy (RT), a critical modality in the treatment of lung cancer, induces direct tumor cell death and augments tumor-specific immunity. However, despite initial tumor control, most patients suffer from locoregional relapse and/or metastatic disease following RT. The use of immunotherapy in non-small-cell lung cancer (NSCLC) could potentially change this outcome by enhancing the effects of RT. Here, we report significant (up to 70% volume reduction of the target lesion) and durable (up to 12 weeks) tumor regressions in conditional
Indexed as
ImmunotherapyAMP-Activated Protein KinasesAnimalsAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell Line, TumorFemaleLung NeoplasmsMaleMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasm Recurrence, LocalProgrammed Cell Death 1 ReceptorProtein Serine-Threonine KinasesAMP-Activated Protein KinasesAntibodies, MonoclonalAntineoplastic AgentsHras protein, mouseProgrammed Cell Death 1 ReceptorProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)Stk11 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.